期刊文献+

冠状动脉易损斑块的药物治疗研究进展 被引量:4

Drug Therapy of Coronary Artery Vulnerable Plaque
下载PDF
导出
摘要 冠状动脉性心脏病患者发生冠状动脉事件的后果十分严重,常危及生命,而易损斑块是导致急性冠脉综合征的主要"罪犯"病变。因此,对易损斑块的早期识别、积极干预,甚至实现冠状动脉斑块的消退,对于急性心血管事件的防治具有非常重要的临床意义。现就冠状动脉易损斑块的药物治疗研究进展做一综述。 Consequences of coronary events of coronary heart disease patients are very serious,often imperiling their lives.Vulnerable plaques are the main 'convicted' lesions leading to acute coronary syndrome.Therefore,early identification,active intervention,even regression of coronary plaques are of great clinical significance to prevention and treatment of acute cardiovascular events.This paper reviews the research progress in drug therapy of coronary artery vulnerable plaque.
出处 《中国全科医学》 CAS CSCD 北大核心 2013年第8期946-948,共3页 Chinese General Practice
关键词 冠状动脉疾病 易损斑块 药物疗法 Coronary artery disease Vulnerable plaque Drug therapy
  • 相关文献

参考文献1

二级参考文献22

  • 1Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
  • 2LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
  • 3Pedersen TR, Faergeman O, Kastelein J J, et al; Incremental Decrease in End Points Through Aggressive Lipid Lowedng (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study:a randomized controlled trial. JAMA. 2005;294:2437-2445.
  • 4Grundy SM, Cleeman JI, Merz CN, et al; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ Guidelines. J Am Coll Cardiol. 2004;44:720-732.
  • 5Blankenhom DH, Azen SP, Kramsch DM, et al;MARS Research Group. Coronary angiographic changes with Iovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med.1993;119:969-976.
  • 6Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed be serial quantitaUve arteriography: the Canadian Coronary Atherosclerosis Intervention Trial(CCAIT). Circulation. 1994;89:959-968.
  • 7Jukema JW, Bruschke AV, van Boven A J, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
  • 8Pitt B, Mancini GB, Ellis SG, Rosrnan HS, Park J-S,McGovem ME. Pravastatin limitaUon of atherosclerosis in the coronary arteries (PLAC Ⅰ): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-1139.
  • 9Brown G, Albers J J, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipidlowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
  • 10MAAS Study Group. Effect of simvastatin on coronary atheroma: the Multicentre Anti-atheroma Study( MAAS). Lancet. 1994;344:633 -638.

共引文献345

同被引文献37

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部